Mazyar Shadman, MD, MPH

Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Medical Oncology
“Your positive attitude and willingness to fight have always inspired me.”
— Dr. Shadman
What do you enjoy about being an academic physician?

Every day, I get to integrate science with the art of human interaction. Seeing patients benefit from medical advances, and being active in pushing the science forward, is extremely rewarding. It’s an exciting time for both cancer care and research. We now have access to a variety of novel therapies that enable us to target cancer cells more specifically without causing major side effects. In my field, we’re always looking for a “cure,” but in the meantime, I’m hopeful that we can relegate cancer to a chronic disease and help patients maintain their desired quality of life.

What is your role in cancer treatment?

A diagnosis of cancer kicks off a torrent of life changes, and in the middle of all this disruption are many important decisions to make about your care. My role is to help you thoroughly understand and weigh your options. At SCCA, you have access to a variety of standard and experimental treatments, from chemotherapy to more novel, targeted approaches that may have fewer side effects. We’ll discuss each option in detail — the potential benefits, the risks and the overall impact on your life and family — so that you can make the best choices for your unique situation.

Provider background

Specialty: Medical Oncology


I am a medical oncologist and stem-cell transplant expert who specializes in treating patients with lymphomas and other blood disorders. My clinical trial work focuses on testing novel agents for the treatment of leukemia and lymphoma, with a particular focus on chronic lymphocytic leukemia (CLL). I also study the clinical outcomes of patients who have already been treated. My goal is to identify patient- or disease-specific characteristics that can help us understand the behavior of a disease and predict its responsiveness to different treatments. One particular area of interest is the epidemiology of hematologic neoplasms (abnormal growth in blood-forming tissue). In 2013, I co-authored a study that found a correlation between certain types of allergies and blood cancers.

Diseases treated

Education, experience and certifications
Medical Degree
Tehran University of Medical Sciences
Cleveland Clinic Foundation, Internal Medicine
University of Washington, Hematology-Oncology
Board Certification
Medical Oncology, 2014; Hematology, 2014; Internal Medicine, 2011, American Board of Internal Medicine
MPH, University of Washington


Understanding treatment options for standard- and high-risk CLL 
Understanding treatment options for standard- and high-risk CLL 

Current treatment options of chronic lymphocytic leukemia (CLL) go far beyond chemotherapy. Thanks to novel agents like ibrutinib, acalabrutinib and venetoclax, there are now chemotherapy-free treatment options that can potentially minimize treatment time and side effects for every patient with CLL.


Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Complete title
Outcomes of Patients with Aggressive B-cell Non-Hodgkin's Lymphoma who Undergo Hematopoietic Cell Transplantation after CAR T-Cell Therapy
Study ID:
Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
Complete title
A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
Study ID:
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Complete title
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome and Richter’s Syndrome


Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.


SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

Dr. Shadman on the Role of MRD in CLL

SCCA's Mazyar Shadman, MD, MPH, was interviewed by OncLive about the role of minimal residual disease in chronic lymphocytic leukemia.

Dr. Shadman on the Potential for CAR T-Cell Therapy in High-Risk CLL

SCCA's Mazyar Shadman, MD, MPH, was interviewed by OncLive about the potential for using CAR T-cell therapy as treatment in patients with high-risk chronic lymphocytic leukemia.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.


SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers